Enhabit, Inc.

Enhabit, Inc.

EHABNYSE / NASDAQHealthcareSmall cap

$13.80+$0.01 (+0.1%)

Last close · Data as of May 14, 2026

Market cap
$706.9M
P/E
-153.7x
EV / EBITDA
20.1x
Revenue
$1.1B
Net margin
-0.4%
ROCE
6.1%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Enhabit, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 14 May 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change +$0.01 (+0.1%) from $13.79 to $13.80 · Last close May 14, 2026

Best weekday to invest, historically

The same weekly amount in EHAB, bought on each weekday since 2022.

News & filings

What Enhabit filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 4.6 million US dollars in fiscal 2025.

Strengths (1)

  • Free cash flow in fiscal 2025 equals 9.3% of the company's market value.
  • Prices are as of 14 May 2026; price-based points are paused until newer prices arrive.

Prices to the 14 May 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services.

Read moreShow less

Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.

Sector
Healthcare
Shares outstanding
50.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$706.9M
P/E
-153.7x
P/B
1.3x
EV / EBITDA
20.1x
EV / Sales
1.1x
P/S
0.7x
52-week high
$14.09
52-week low
$6.52

Profitability

Operating margin
6.0%
Net margin
-0.4%
EBITDA margin
5.5%
ROE
-0.9%
ROCE
6.1%
ROIC
2.3%
ROA
-0.4%
Asset turnover
0.91

Growth

Revenue
$1.1B
Revenue growth, 1Y
2.4%
Revenue CAGR, 3Y
-0.3%
Net profit growth, 1Y
-97.1%
Free cash flow
$65.8M

Solvency

Current ratio
1.63
Debt / Equity
0.94
Debt / Assets
0.43
CFO / Net profit
-15.37
Cash / Market cap
6.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$1.1B
Cost of revenue$540.2M
Gross profit$519.8M
Operating expenses$456.0M
Selling, general and administrative$433.5M
Operating income$63.8M
Interest and other-$62.4M
Pretax income$1.4M
Tax and other$6.0M
Net income-$4.6M

Revenue and net profit

Revenue grew 2.4% in FY2025; net profit is the dashed line.

Enhabit, Inc. revenue and net profit by fiscal year
Enhabit, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.1B-$40.4M
FY2023$1.0B-$80.5M
FY2024$1.0B-$156.2M
FY2025$1.1B-$4.6M

Cash flows

FY2025: $70.7M from operations, $65.8M free after investment (dashed).

Enhabit, Inc. operating and free cash flow by fiscal year
Enhabit, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$80.1M$73.0M
FY2023$48.4M$44.9M
FY2024$51.2M$47.4M
FY2025$70.7M$65.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.1B+2.4%1Y
EBITDA
$57.9M
Net profit
-$4.6M
Cash from operations
$70.7M+38.1%1Y
Free cash flow
$65.8M+38.8%1Y
Revenue CAGR, 3Y
-0.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.1B$57.9M-$4.6M$65.8M-0.9%+2.4%-97.1%

Monthly returns

Month-by-month returns of EHAB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.2B
Liabilities$603.0M
Equity$564.1M
Paid-in capital$443.6M
Retained earnings$93.7M
Treasury stock$3.8M
Minority interest$30.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; EHAB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. CBLL7.8x
  2. Enhabit, Inc. (this company)1.1x

Not shown (no positive earnings and no EV / Sales): Bright Minds Biosciences Inc., Solid Biosciences Inc., Allogene Therapeutics, Inc., Aura Biosciences, Inc., Candel Therapeutics, Inc., Design Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Enhabit, Inc.EHABthis company$706.9M-153.7x1.3x-0.9%20.1x
HealthStream, Inc.HSTM$738.9M40.3x2.1x5.2%11.3x
Bright Minds Biosciences Inc.DRUG$731.0M-59.8x8.9x-14.9%-46.8x
Solid Biosciences Inc.SLDB$712.8M-4.1x4.0x-96.8%-3.8x
CBLLCBLL$711.4M-13.3x4.6x-34.4%-13.8x
Allogene Therapeutics, Inc.ALLO$704.1M-3.7x2.4x-65.3%-4.1x
Aura Biosciences, Inc.AURA$703.0M-6.6x5.1x-77.6%-5.9x
Candel Therapeutics, Inc.CADL$679.2M-17.8x13.1x-73.5%-17.3x
Design Therapeutics, Inc.DSGN$672.0M-9.6x3.2x-32.8%-8.3x
Peer median—-8.1x4.3x-49.8%-7.1x

Year-to-date ROI

EHAB since 1 January, against earlier years.

Historical volatility

EHAB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Enhabit, Inc. operating margin by fiscal year
Enhabit, Inc. operating margin by fiscal year
DateOperating margin
FY20229.1%
FY20233.7%
FY20244.5%
FY20256.0%
LineFY2025
Cost of revenueCost Of Revenue$540.2M
Gross profitGross Profit$519.8M
Operating expensesOperating Expense$456.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$22.5M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$22.5M
Total expensesTotal Expenses$996.2M
Pretax incomePretax Income$1.4M

Learn while you research

Academy chapters picked for Enhabit, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →